Free Trial

Belite Bio (BLTE) News Today

$49.96
-0.14 (-0.28%)
(As of 06/14/2024 ET)
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Increases By 32.2%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 46,800 shares, an increase of 32.2% from the May 15th total of 35,400 shares. Based on an average daily trading volume, of 43,500 shares, the days-to-cover ratio is currently 1.1 days.
Belite Bio (NASDAQ:BLTE) Given "Buy" Rating at HC Wainwright
Belite Bio's (BLTE) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reissued a "buy" rating and set a $59.00 price target on shares of Belite Bio in a research report on Thursday.
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High at $49.25
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week High at $49.25
Armistice Capital LLC Buys New Holdings in Belite Bio, Inc (NASDAQ:BLTE)
Armistice Capital LLC bought a new stake in Belite Bio, Inc (NASDAQ:BLTE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,000 shares of the company's stock, valued at approximately
Belite Bio (NASDAQ:BLTE) Shares Down 2.8%
Belite Bio (NASDAQ:BLTE) Shares Down 2.8%
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High at $49.16
Belite Bio (NASDAQ:BLTE) Hits New 12-Month High at $49.16
Belite Bio, Inc (NASDAQ:BLTE) Sees Significant Increase in Short Interest
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 35,400 shares, a growth of 87.3% from the April 30th total of 18,900 shares. Based on an average daily trading volume, of 40,100 shares, the days-to-cover ratio is presently 0.9 days.
Belite Bio, Inc (NASDAQ:BLTE) Given Consensus Recommendation of "Buy" by Brokerages
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that
FY2024 Earnings Estimate for Belite Bio, Inc Issued By Cantor Fitzgerald (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for Belite Bio in a research note issued to investors on Wednesday, May 15th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings of ($1.04) per s
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from Benchmark
Benchmark reissued a "buy" rating and set a $57.00 target price on shares of Belite Bio in a research report on Thursday.
Belite Bio (NASDAQ:BLTE) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $59.00 price target on shares of Belite Bio in a research note on Wednesday.
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 44.4% in April
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 18,900 shares, a drop of 44.4% from the April 15th total of 34,000 shares. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is presently 0.5 days.
Belite Bio (BLTE) to Release Earnings on Tuesday
Belite Bio (NASDAQ:BLTE) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports.
Belite Bio (NASDAQ:BLTE) Shares Gap Down to $43.20
Belite Bio (NASDAQ:BLTE) Shares Gap Down to $43.20
BLTE Belite Bio, Inc
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Declines By 13.0%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 34,000 shares, a decrease of 13.0% from the March 31st total of 39,100 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is presently 0.7 days.
Belite Bio (NASDAQ:BLTE) Trading 6.7% Higher
Belite Bio (NASDAQ:BLTE) Shares Up 6.7%
Belite Bio Inc ADR
Belite Bio, Inc (NASDAQ:BLTE) Sees Large Drop in Short Interest
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 39,100 shares, a decline of 34.3% from the March 15th total of 59,500 shares. Based on an average daily volume of 61,400 shares, the days-to-cover ratio is currently 0.6 days.
Belite Bio (NASDAQ:BLTE) Shares Gap Down to $39.98
Belite Bio (NASDAQ:BLTE) Shares Gap Down to $39.98
Belite Bio (NASDAQ:BLTE) Stock Price Down 1.8%
Belite Bio (NASDAQ:BLTE) Shares Down 1.8%
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Grows By 20.7%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 59,500 shares, a growth of 20.7% from the February 29th total of 49,300 shares. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is presently 0.8 days.
Belite Bio (NASDAQ:BLTE) Shares Down 4.8%
Belite Bio (NASDAQ:BLTE) Trading Down 4.8%
Belite Bio's (BLTE) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $59.00 target price on shares of Belite Bio in a research report on Friday.
Belite Bio, Inc Expected to Post Q1 2024 Earnings of ($0.40) Per Share (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Belite Bio in a note issued to investors on Monday, March 18th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share
Belite Bio, Inc to Post FY2028 Earnings of $4.45 Per Share, Leerink Partnrs Forecasts (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Leerink Partnrs cut their FY2028 earnings per share estimates for Belite Bio in a research note issued on Monday, March 18th. Leerink Partnrs analyst M. Goodman now expects that the company will earn $4.45 per share for the year

BLTE Media Mentions By Week

BLTE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLTE
News Sentiment

0.45

0.89

Average
Medical
News Sentiment

BLTE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLTE Articles
This Week

8

2

BLTE Articles
Average Week

Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BLTE) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners